No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life

Anne M. Plomgaard, Thomas Alderliesten, Frank van Bel, Manon Benders, Olivier Claris, Malaika Cordeiro, Eugene Dempsey, Monica Fumagalli, Christian Gluud, Simon Hyttel-Sorensen, Petra Lemmers, Adelina Pellicer, Gerhard Pichler, Gorm Greisen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: Cerebral hypoxia has been associated with neurodevelopmental impairment. We studied whether reducing cerebral hypoxia in extremely preterm infants during the first 72 hours of life affected neurological outcomes at two years of corrected age. Methods: In 2012-2013, the phase II randomised Safeguarding the Brains of our smallest Children trial compared visible cerebral near-infrared spectroscopy (NIRS) monitoring in an intervention group and blinded NIRS monitoring in a control group. Cerebral hypoxia was significantly reduced in the intervention group. We followed up 115 survivors from eight European centres at two years of corrected age, by conducting a medical examination and assessing their neurodevelopment with the Bayley Scales of Infant and Toddler Development, Second or Third Edition, and the parental Ages and Stages Questionnaire (ASQ). Results: There were no differences between the intervention (n = 65) and control (n = 50) groups with regard to the mean mental developmental index (89.6 ± 19.5 versus 88.4 ± 14.7, p = 0.77), ASQ score (215 ± 58 versus 213 ± 58, p = 0.88) and the number of children with moderate-to-severe neurodevelopmental impairment (10 versus six, p = 0.58). Conclusions: Cerebral NIRS monitoring was not associated with long-term benefits or harm with regard to neurodevelopmental outcome at two years of corrected age.

Original languageEnglish
Pages (from-to)275-281
JournalActa Paediatrica, International Journal of Paediatrics
Volume108
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint

Brain Hypoxia
Oximetry
Near-Infrared Spectroscopy
Premature Infants
Extremely Premature Infants
Child Development
Survivors
Parents
Control Groups
Brain
Surveys and Questionnaires

Keywords

  • Ages and stages questionnaire
  • Bayley scales of infant and toddler development
  • Cerebral near-infrared spectroscopy
  • Extremely preterm infants
  • Neurodevelopment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life. / Plomgaard, Anne M.; Alderliesten, Thomas; van Bel, Frank; Benders, Manon; Claris, Olivier; Cordeiro, Malaika; Dempsey, Eugene; Fumagalli, Monica; Gluud, Christian; Hyttel-Sorensen, Simon; Lemmers, Petra; Pellicer, Adelina; Pichler, Gerhard; Greisen, Gorm.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 108, No. 2, 2019, p. 275-281.

Research output: Contribution to journalArticle

Plomgaard, AM, Alderliesten, T, van Bel, F, Benders, M, Claris, O, Cordeiro, M, Dempsey, E, Fumagalli, M, Gluud, C, Hyttel-Sorensen, S, Lemmers, P, Pellicer, A, Pichler, G & Greisen, G 2019, 'No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life', Acta Paediatrica, International Journal of Paediatrics, vol. 108, no. 2, pp. 275-281. https://doi.org/10.1111/apa.14463
Plomgaard, Anne M. ; Alderliesten, Thomas ; van Bel, Frank ; Benders, Manon ; Claris, Olivier ; Cordeiro, Malaika ; Dempsey, Eugene ; Fumagalli, Monica ; Gluud, Christian ; Hyttel-Sorensen, Simon ; Lemmers, Petra ; Pellicer, Adelina ; Pichler, Gerhard ; Greisen, Gorm. / No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life. In: Acta Paediatrica, International Journal of Paediatrics. 2019 ; Vol. 108, No. 2. pp. 275-281.
@article{7d7ce8f3165a4c04899aeeaa3f21ffe3,
title = "No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life",
abstract = "Aim: Cerebral hypoxia has been associated with neurodevelopmental impairment. We studied whether reducing cerebral hypoxia in extremely preterm infants during the first 72 hours of life affected neurological outcomes at two years of corrected age. Methods: In 2012-2013, the phase II randomised Safeguarding the Brains of our smallest Children trial compared visible cerebral near-infrared spectroscopy (NIRS) monitoring in an intervention group and blinded NIRS monitoring in a control group. Cerebral hypoxia was significantly reduced in the intervention group. We followed up 115 survivors from eight European centres at two years of corrected age, by conducting a medical examination and assessing their neurodevelopment with the Bayley Scales of Infant and Toddler Development, Second or Third Edition, and the parental Ages and Stages Questionnaire (ASQ). Results: There were no differences between the intervention (n = 65) and control (n = 50) groups with regard to the mean mental developmental index (89.6 ± 19.5 versus 88.4 ± 14.7, p = 0.77), ASQ score (215 ± 58 versus 213 ± 58, p = 0.88) and the number of children with moderate-to-severe neurodevelopmental impairment (10 versus six, p = 0.58). Conclusions: Cerebral NIRS monitoring was not associated with long-term benefits or harm with regard to neurodevelopmental outcome at two years of corrected age.",
keywords = "Ages and stages questionnaire, Bayley scales of infant and toddler development, Cerebral near-infrared spectroscopy, Extremely preterm infants, Neurodevelopment",
author = "Plomgaard, {Anne M.} and Thomas Alderliesten and {van Bel}, Frank and Manon Benders and Olivier Claris and Malaika Cordeiro and Eugene Dempsey and Monica Fumagalli and Christian Gluud and Simon Hyttel-Sorensen and Petra Lemmers and Adelina Pellicer and Gerhard Pichler and Gorm Greisen",
year = "2019",
doi = "10.1111/apa.14463",
language = "English",
volume = "108",
pages = "275--281",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life

AU - Plomgaard, Anne M.

AU - Alderliesten, Thomas

AU - van Bel, Frank

AU - Benders, Manon

AU - Claris, Olivier

AU - Cordeiro, Malaika

AU - Dempsey, Eugene

AU - Fumagalli, Monica

AU - Gluud, Christian

AU - Hyttel-Sorensen, Simon

AU - Lemmers, Petra

AU - Pellicer, Adelina

AU - Pichler, Gerhard

AU - Greisen, Gorm

PY - 2019

Y1 - 2019

N2 - Aim: Cerebral hypoxia has been associated with neurodevelopmental impairment. We studied whether reducing cerebral hypoxia in extremely preterm infants during the first 72 hours of life affected neurological outcomes at two years of corrected age. Methods: In 2012-2013, the phase II randomised Safeguarding the Brains of our smallest Children trial compared visible cerebral near-infrared spectroscopy (NIRS) monitoring in an intervention group and blinded NIRS monitoring in a control group. Cerebral hypoxia was significantly reduced in the intervention group. We followed up 115 survivors from eight European centres at two years of corrected age, by conducting a medical examination and assessing their neurodevelopment with the Bayley Scales of Infant and Toddler Development, Second or Third Edition, and the parental Ages and Stages Questionnaire (ASQ). Results: There were no differences between the intervention (n = 65) and control (n = 50) groups with regard to the mean mental developmental index (89.6 ± 19.5 versus 88.4 ± 14.7, p = 0.77), ASQ score (215 ± 58 versus 213 ± 58, p = 0.88) and the number of children with moderate-to-severe neurodevelopmental impairment (10 versus six, p = 0.58). Conclusions: Cerebral NIRS monitoring was not associated with long-term benefits or harm with regard to neurodevelopmental outcome at two years of corrected age.

AB - Aim: Cerebral hypoxia has been associated with neurodevelopmental impairment. We studied whether reducing cerebral hypoxia in extremely preterm infants during the first 72 hours of life affected neurological outcomes at two years of corrected age. Methods: In 2012-2013, the phase II randomised Safeguarding the Brains of our smallest Children trial compared visible cerebral near-infrared spectroscopy (NIRS) monitoring in an intervention group and blinded NIRS monitoring in a control group. Cerebral hypoxia was significantly reduced in the intervention group. We followed up 115 survivors from eight European centres at two years of corrected age, by conducting a medical examination and assessing their neurodevelopment with the Bayley Scales of Infant and Toddler Development, Second or Third Edition, and the parental Ages and Stages Questionnaire (ASQ). Results: There were no differences between the intervention (n = 65) and control (n = 50) groups with regard to the mean mental developmental index (89.6 ± 19.5 versus 88.4 ± 14.7, p = 0.77), ASQ score (215 ± 58 versus 213 ± 58, p = 0.88) and the number of children with moderate-to-severe neurodevelopmental impairment (10 versus six, p = 0.58). Conclusions: Cerebral NIRS monitoring was not associated with long-term benefits or harm with regard to neurodevelopmental outcome at two years of corrected age.

KW - Ages and stages questionnaire

KW - Bayley scales of infant and toddler development

KW - Cerebral near-infrared spectroscopy

KW - Extremely preterm infants

KW - Neurodevelopment

UR - http://www.scopus.com/inward/record.url?scp=85050619115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050619115&partnerID=8YFLogxK

U2 - 10.1111/apa.14463

DO - 10.1111/apa.14463

M3 - Article

AN - SCOPUS:85050619115

VL - 108

SP - 275

EP - 281

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 2

ER -